An interventional study of JenaValve Pericardial TAVR System in Aortic Valve Stenosis, Heart Valve Diseases and Heart Diseases, sponsored by JenaValve Technology, Inc.. Status unknown at 13 sites in 4 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2022-11-22.
Sponsored by JenaValve Technology, Inc. · Not applicable, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 191 studies in Aortic Valve Stenosis with a site in Germany — 39 open to participants now, 58 under way, 3 of them phase 3. Aortic Valve Stenosis · Germany.
Among the 191 studies in Aortic Valve Stenosis with a site in Germany, this one is the 72nd largest by enrollment of the 93 interventional ones that give a count, is one of 13 that started in 2016, is one of 82 with no phase, and was the 75th registered.
1,028 studies on the registry are indexed under Aortic Valve Stenosis; 295 are open to participants now.
Browse Aortic Valve Stenosis studies →39 of the 191 studies in Aortic Valve Stenosis with a site in Germany are open now. Recruiting first, the newest first:
Erasmus Medical Center · Sites in Germany, Netherlands
Ages 70+
IHF GmbH - Institut für Herzinfarktforschung · Sites in Germany
Ages 18+
Idoven 1903 S.L. · Sites in Germany
Ages 18+ · Healthy volunteers
Institut für Pharmakologie und Präventive Medizin · Sites in Germany
Ages 18+
Ceric Sàrl · Sites in Germany, Austria, Estonia and 11 more countries
Ages 65–75
A study can be open while its sites in Germany have not opened yet or have stopped. Only those recruiting at a site in Germany →
Of the 209 Aortic Valve Stenosis studies recruiting now, 163 (78%) set no upper age limit and 9 (4%) stop at 75 or younger; 24 take children under 18; 14 take healthy volunteers.
This study: 18 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
191 studies; the count open now beside each. This study's row is marked.
First in 2001; this study’s year is marked. 13 started in 2016.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 68 is below the median of 126 across 555 interventional studies indexed under Aortic Valve Stenosis.
Median enrollment 220 across the 93 interventional studies, 300 across the 98 observational. Of the 109 that completed or were terminated, 28 (26%) have results posted.
This tab as a report to print or save as PDF → With an account.
93 of 191 have an industry lead sponsor. The 10 most frequent:
JenaValve Technology, Inc. is the lead sponsor of 8 studies on the registry; 1 is open to participants now.
JenaValve Technology, Inc. has 4 studies filed under Aortic Valve Stenosis — fewer than ten, so there is no comparison to draw.
7 of the studies in Aortic Valve Stenosis with a site in Germany that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT07479992Idoven 1903 S.L.Multicenter Study for the Validation of Willem AI: Aortic StenoSis Early Diagnosis With AI-electrocardiogram Study | 2027-01 |
| NCT06493994University of LuebeckMyval TransAXillary Transcatheter Aortic Valve Replacement Multicenter Clinical Registry | 2027-01-30 |
| NCT05932615Abbott Medical DevicesENVISION IDE Trial: Safety and Effectiveness of NAVITOR in Transcatheter Aortic Valve Implantation | 2027-04 |
| NCT07520591Cardiawave SAValvosoft Outcomes Registry for Real-World Evidence | 2027-06-30 |
| NCT05603520Heinrich-Heine University, DuesseldorfPhenotyping Heterogeneity and Regionality of the Aorta | 2027-06-30 |
Add all 7 to your calendar (.ics) → With an account.
Among the 191 studies in Aortic Valve Stenosis with a site in Germany, from their registry updates:
This tab as a report to print or save as PDF → With an account.
To collect information about treatment for severe aortic stenosis (AS), which affects the aortic valve in the heart. Aortic stenosis is a narrowing of the aortic valve opening, which decreases blood flow from the heart and causes symptoms such as chest pain, fainting and shortness of breath. The preferred treatment for severe aortic stenosis is aortic valve replacement surgery.
This study will examine the use of a TAVR (Transcatheter Aortic Valve Replacement), which is a minimally invasive procedure designed to replace the aortic valve inside the heart. This less invasive surgical approach called TAVR is offered to those patients who are high risk for undergoing open heart surgery to replace the aortic valve. In this study, TAVR will be performed using the JenaValve Pericardial TAVR System.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
The New York Heart Association’s four classes of how much heart failure limits physical activity.
Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.
NYHA class (heart failure)
The New York Heart Association’s four classes of how much heart failure limits physical activity.
Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Transcatheter aortic valve replacement (TAVR) will be performed using the JenaValve pericardial valve and delivery system.
Device: JenaValve Pericardial TAVR System
Transcatheter aortic valve replacement (TAVR) will be performed using the JenaValve Pericardial valve and delivery system.
All-Cause Mortality
All-cause mortality rate at 30 Day
Time frame: 30 Day
Myocardial Infarction
Peri-procedural and spontaneous myocardial infarction
Time frame: 30 Day
All Stroke/TIA
Neurological Complications
Time frame: 30 Day
Major Bleeding
Life threatening or major bleeding
Time frame: 30 Day
Major Vascular Complication
Major vascular and bleeding complications
Time frame: 30 Day
Conduction Disturbance and Arrhythmias
Conduction system injury (defect), including AV block, which may require a permanent pacemaker
Time frame: 30 Day
Acute Kidney Injury (AKI)
Number of patients who were diagnosed with AKI Stage 2 or 3: AKI Stage 2: Increase in serum creatinine to 200%-299% (2.0%-2.99% increase compared with baseline) OR urine output \<0.5 mL/kg/h for \>12 but \<24 h AKI Stage 3: Increase in serum creatinine to ≥300% (\>3 × increase compared with baseline) OR serum creatinine of ≥4.0 mg/dL (≥354 mmol/L) with an acute increase of at least 0.5 mg/dL (44 mmol/L) OR urine output \<0.3 ml/kg/h for ≥24 h OR anuria for ≥12 h
Time frame: 30 Day
Coronary Obstruction Requiring Intervention
Coronary obstruction post-implant requiring intervention
Time frame: 30 Day
Endocarditis
Bacterial endocarditis
Time frame: 30 Day
Conversion to Surgical Aortic Valve Replacement (SAVR)
Number of patients who underwent conversion to open sternotomy during the TAVR procedure secondary to any procedure-related complications
Time frame: 30 Day
THV Malpositioning
Number of patients who experienced: Migration: After initial correct positioning, the valve prosthesis moves upwards or downwards, within the aortic annulus from its initial position, with or without consequences Embolization: The valve prosthesis moves during or after deployment such that it loses contact with the aortic annulus Ectopic Valve Deployment: Permanent deployment of the valve prosthesis in a location other than the aortic root
Time frame: 30 Day
| Milestone | Transcatheter Aortic Valve Replacement (TAVR) |
|---|---|
| Started | 68 |
| Completed | 68 |
| Not completed | 0 |
All-cause mortality rate at 30 Day
| Participants | Transcatheter Aortic Valve Replacement (TAVR) |
|---|---|
| All-Cause Mortality | 2 |
Peri-procedural and spontaneous myocardial infarction
| Participants | Transcatheter Aortic Valve Replacement (TAVR) |
|---|---|
| Myocardial Infarction | 1 |
Neurological Complications
| Participants | Transcatheter Aortic Valve Replacement (TAVR) |
|---|---|
| All Stroke/TIA | 6 |
Life threatening or major bleeding
| Participants | Transcatheter Aortic Valve Replacement (TAVR) |
|---|---|
| Major Bleeding | 4 |
Major vascular and bleeding complications
| Participants | Transcatheter Aortic Valve Replacement (TAVR) |
|---|---|
| Major Vascular Complication | 5 |
Conduction system injury (defect), including AV block, which may require a permanent pacemaker
| Participants | Transcatheter Aortic Valve Replacement (TAVR) |
|---|---|
| Conduction Disturbance and Arrhythmias | 10 |
Number of patients who were diagnosed with AKI Stage 2 or 3: AKI Stage 2: Increase in serum creatinine to 200%-299% (2.0%-2.99% increase compared with baseline) OR urine output \<0.5 mL/kg/h for \>12 but \<24 h AKI Stage 3: Increase in serum creatinine to ≥300% (\>3 × increase compared with baseline) OR serum creatinine of ≥4.0 mg/dL (≥354 mmol/L) with an acute increase of at least 0.5 mg/dL (44 mmol/L) OR urine output \<0.3 ml/kg/h for ≥24 h OR anuria for ≥12 h
| Participants | Transcatheter Aortic Valve Replacement (TAVR) |
|---|---|
| Acute Kidney Injury (AKI) | 0 |
Coronary obstruction post-implant requiring intervention
| Participants | Transcatheter Aortic Valve Replacement (TAVR) |
|---|---|
| Coronary Obstruction Requiring Intervention | 0 |
Bacterial endocarditis
| Participants | Transcatheter Aortic Valve Replacement (TAVR) |
|---|---|
| Endocarditis | 0 |
Number of patients who underwent conversion to open sternotomy during the TAVR procedure secondary to any procedure-related complications
| Participants | Transcatheter Aortic Valve Replacement (TAVR) |
|---|---|
| Conversion to Surgical Aortic Valve Replacement (SAVR) | 1 |
Number of patients who experienced: Migration: After initial correct positioning, the valve prosthesis moves upwards or downwards, within the aortic annulus from its initial position, with or without consequences Embolization: The valve prosthesis moves during or after deployment such that it loses contact with the aortic annulus Ectopic Valve Deployment: Permanent deployment of the valve prosthesis in a location other than the aortic root
| Participants | Transcatheter Aortic Valve Replacement (TAVR) |
|---|---|
| THV Malpositioning | 3 |
Collected over 30 day. Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Transcatheter Aortic Valve Replacement (TAVR) | 2/68 (2.9%) | 39/68 (57.4%) | 23/68 (33.8%) |
| Event | Transcatheter Aortic Valve Replacement (TAVR) |
|---|---|
| Other InfectionInfections and infestations | 8/68 |
| Bleeding ComplicationBlood and lymphatic system disorders | 5/68 |
| Conduction DisturbanceCardiac disorders | 5/68 |
| Stroke/TIANervous system disorders | 4/68 |
| Bleeding (Major)Blood and lymphatic system disorders | 3/68 |
| GI ComplicationGastrointestinal disorders | 3/68 |
| Heart FailureCardiac disorders | 3/68 |
| PneumoniaInfections and infestations | 3/68 |
| Arterial OcclusionCardiac disorders | 2/68 |
| Exacerbation COPDRespiratory, thoracic and mediastinal disorders | 2/68 |
| Event | Transcatheter Aortic Valve Replacement (TAVR) |
|---|---|
| OtherGeneral disorders | 17/68 |
| Bleeding ComplicationBlood and lymphatic system disorders | 5/68 |
| Respiratory ComplicationRespiratory, thoracic and mediastinal disorders | 5/68 |
| Chest PainGeneral disorders | 4/68 |
Enrolled
| Age, Continuous(years) | Transcatheter Aortic Valve Replacement (TAVR) |
|---|---|
| Mean | 83 ± 5 |
| Sex: Female, Male(Participants) | Transcatheter Aortic Valve Replacement (TAVR) |
|---|---|
| Female | 44 |
| Male | 24 |
| Race and Ethnicity Not Collected(Participants) | Transcatheter Aortic Valve Replacement (TAVR) |
|---|
PDFs hosted by the registry, ClinicalTrials.gov.
Plan to share: No
Ran from Oct 2016 to primary completion in May 2019, 31 months.
Results were first posted in Nov 2022, 3 years 5 months after primary completion.
Of 111 industry-sponsored interventional studies with no phase under Aortic Valve Stenosis, half reached primary completion within 29 months of starting (the median), counting those still running; a quarter within 16 and three quarters within 54. This study's 31 months is close to that.
Counting every sponsor, half of 288 studies reached it within 33 months; a quarter within 18 and three quarters within 71.
How these figures are worked out, and which studies are left out of them.
This study is status unknown, as verified in Oct 2022. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
JenaValve Technology, Inc.